[Federal Register: May 21, 2003 (Volume 68, Number 98)]
[Notices]
[Page 27820]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr21my03-49]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 02N-0452]
Agency Information Collection Activities; Announcement of OMB
Approval; New Drugs and Biological Drug Products; Evidence Needed to
Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are
Not Ethical or Feasible
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled ``New Drugs and Biological Drug
Products; Evidence Needed to Demonstrate Effectiveness of New Drugs
When Human Efficacy Studies Are Not Ethical or Feasible'' has been
approved by the Office of Management and Budget (OMB) under the
Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT: Karen L. Nelson, Office of Information
Resources Management (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-1482.
SUPPLEMENTARY INFORMATION: In the Federal Register of March 7, 2003 (68
FR 11119), the agency announced that the proposed information
collection had been submitted to OMB for review and clearance under 44
U.S.C. 3507. An agency may not conduct or sponsor, and a person is not
required to respond to, a collection of information unless it displays
a currently valid OMB control number. OMB has now approved the
information collection and has assigned OMB control number 0910-0423.
The approval expires on May 31, 2006. A copy of the supporting
statement for this information collection is available on the Internet
at http://www.fda.gov/ohrms/dockets.
Dated: May 15, 2003.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 03-12723 Filed 5-20-03; 8:45 am]
BILLING CODE 4160-01-S